Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00255476 | The IRESSA Novel Head and Neck Chemotherapy Evaluation Study | PHASE2 | COMPLETED | 64 | — | — | Feb 1, 2004 | Jul 1, 2007 | Apr 23, 2009 | 1 | United Kingdom |
| Name | Type | Description |
|---|---|---|
| gefitinib | DRUG | - |
| cisplatin | DRUG | - |
| 5-flourouracil | DRUG | - |
Inclusion Criteria: * Provision of written informed consent * Patients with histologically proven primary SCCHN * Aged 18 or over Exclusion Criteria: * Patients eligible for surgery with curative intent * Other co-existing malignancies diagnosed within the last 5 years with the exception of basal...